Amniotic Fluid MMP-9 and Neurotrophins in Autism Spectrum Disorders: An Exploratory Study

Autism Research

Volumn 5, Issue 6, 2012, Pages 428-433

  Abdallah, Morsi W ^a,b,c   Pearce, Brad D ^d   Larsen, Nanna ^b   Greaves Lord, Kirstin ^e,f   Nørgaard Pedersen, Bent ^b   Hougaard, David M ^b   Mortensen, Erik L ^g   Grove, Jakob ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d EMORY UNIVERSITY   (United States)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f Yulius Academie and Yulius Autisme   (Netherlands)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amniotic fluid; Autistic disorder; Matrix metalloproteinase; Neuronal plasticity; Neurotrophins

Indexed keywords

GELATINASE B; NEUROTROPHIN 4; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AMNION FLUID; ARTICLE; AUTISM; CONTROLLED STUDY; DENMARK; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NERVE CELL PLASTICITY; PRIORITY JOURNAL;

ADULT; AMNIOTIC FLUID; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COHORT STUDIES; DENMARK; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MATRIX METALLOPROTEINASE 9; NERVE GROWTH FACTORS; NEURONAL PLASTICITY; ODDS RATIO; PREGNANCY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871400695     PISSN: 19393792     EISSN: 19393806     Source Type: Journal    
DOI: 10.1002/aur.1254     Document Type: Article

References (32)

1. Andersen, T.F., Madsen, M., Jorgensen, J., Mellemkjaer, L., & Olsen, J.H. (1999). The Danish National Hospital Register. A valuable source of data for modern health sciences. Danish Medical Bulletin, 46, 263-268.
2. Bilousova, T.V., Dansie, L., Ngo, M., Aye, J., Charles, J.R., etal. (2009). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. Journal of Medical Genetics, 46, 94-102. doi:10.1136/jmg.2008.061796
3. Cajigas, I.J., Will, T., & Schuman, E.M. (2010). Protein homeostasis and synaptic plasticity. EMBO Journal, 29, 2746-2752. doi:10.1038/emboj.2010.173
4. Ethell, I.M., & Ethell, D.W. (2007). Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets. Journal of Neuroscience Research, 85, 2813-2823. doi:10.1002/jnr.21273
5. Ganea, E., Trifan, M., Laslo, A.C., Putina, G., & Cristescu, C. (2007). Matrix metalloproteinases: Useful and deleterious. Biochemical Society Transactions, 35, 689-691.
6. Gillberg, C., & Billstedt, E. (2000). Autism and Asperger syndrome: Coexistence with other clinical disorders. Acta Psychiatrica Scandinavica, 102, 321-330. doi:10.1034/j.1600-0447.2000.102005321.x
7. Hagerman, R., Hoem, G., & Hagerman, P. (2010). Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Molecular Autism, 1, 1-14. doi:10.1186/2040-2392-1-12
8. Harrington, J.W. (2010). The actual prevalence of autism: Are we there yet? Pediatrics, 126, e1257-e1258. doi:10.1542/peds.2010-2305
9. Huang, E.J., & Reichardt, L.F. (2001). Neurotrophins: Roles in neuronal development and function*. Annual Review of Neuroscience, 24, 677-736. doi:10.1146/annurev.neuro.24.1.677
10. Knudsen, L.B., & Olsen, J. (1998). The Danish Medical Birth Registry. Danish Medical Bulletin, 45, 320-323.
11. Krueger, D.D., & Bear, M.F. (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annual Review of Medicine, 62, 411-429. doi:10.1146/annurev-med-061109-134644
12. Kugler, K.G., Hackl, W.O., Mueller, L.A.J., Fiegl, H., Graber, A., & Pfeiffer, R.M. (2011). The impact of sample storage time on estimates of association in biomarker discovery studies. Journal of Clinical Bioinformatics, 1, 9. doi:10.1186/2043-9113-1-9
13. Larsson, H.J., Eaton, W.W., Madsen, K.M., Vestergaard, M., Olesen, A.V., etal. (2005). Risk factors for autism: Perinatal factors, parental psychiatric history, and socioeconomic status. American Journal of Epidemiology, 161, 916-925. doi:10.1093/aje/kwi123
14. Lauritsen, M.B., Jørgensen, M., Madsen, K.M., Lemcke, S., Toft, S., etal. (2010). Validity of childhood autism in the Danish Psychiatric Central Register: Findings from a cohort sample born 1990-1999. Journal of Autism and Developmental Disorders, 40, 139-148. doi:10.1007/s10803-009-0818-0
15. Lauritsen, M.B., Pedersen, C.B., & Mortensen, P.B. (2004). The incidence and prevalence of pervasive developmental disorders: A Danish population-based study. Psychological Medicine, 34, 1339-1346. doi:10.1017/S0033291704002387
16. Luminex Corporation. (2009). Cytokines, Chemokines, and Growth Factors, 20-Oct.-2009. Retrieved 20 October 2009, from http://www.luminexcorp.com/applications/cytokine.html
17. Markram, K., & Markram, H. (2010). The intense world theory-A unifying theory of the neurobiology of autism. [Review]. Frontiers in Human Neuroscience, 4, 1-29. doi:10.3389/fnhum.2010.00224
18. McAllister, A.K., Katz, L.C., & Lo, D.C. (1999). Neurotrophins and synaptic plasticity. Annual Review of Neuroscience, 22, 295-318. doi:10.1146/annurev.neuro.22.1.295
19. Munk-Jorgensen, P., & Mortensen, P.B. (1997). The Danish Psychiatric Central Register. Danish Medical Bulletin, 44, 82-84.
20. Newschaffer, C.J., Croen, L.A., Daniels, J., Giarelli, E., Grether, J.K., etal. (2007). The epidemiology of autism spectrum disorders. Annual Review of Public Health, 28, 235-258. doi:10.1146/annurev.publhealth.28.021406.144007
21. Nickl-Jockschat, T., & Michel, T.M. (2011). The role of neurotrophic factors in autism. Molecular Psychiatry, 16, 478-490.
22. Nørgaard-Pedersen, B. (2005). Statens Serum Institut: Etablering af en ny historisk prospektiv mor-barn biobank kohorte baseret på ca. 100.000 gravidscreenings prøver [Grant Application: Establishing a new historic prospective mother-child cohort based on approximately 100, 000 antenatal screening samples at Statens Serum Institut]. Copenhagen: Statens Sundhedsvidenskabelige Forskningsråd.
23. Nørgaard-Pedersen, B., & Hougaard, D.M. (2007). Storage policies and use of the Danish Newborn Screening Biobank. Journal of Inherited Metabolic Disease, 30, 530-536.
24. Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., etal. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurology, 10, 91.
25. Rosenberg, G.A., & Yang, Y. (2007). Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurgical Focus, 22, 1-9. doi:10.3171/foc.2007.22.5.5
26. Skogstrand, K., Thorsen, P., Norgaard-Pedersen, B., Schendel, D.E., Sorensen, L.C., & Hougaard, D.M. (2005). Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clinical Chemistry, 51, 1854-1866. doi:10.1373/clinchem.2005.052241
27. SPSS Inc. (2009). IBM PASW® Statistics 18 (SPSS Statistics 18) (Version 18). Chicago, IL. Retrieved 15 September 2010, from http://www.spss.com/statistics/
28. StataCorp LP. (2009). Stata Statistics/Data Analysis (Version 11.2). College Station, TX. Retrieved 5 January 2011, from http://www.stata.com/stata11/index.html
29. Sundhedsstyrelsen. (1986). Klassifikation af Sygdomme [Danish-Latin version of International Classification of Diseases, 8th revision, 1965], 2nd ed. Vol. Systematisk Del. Copenhagen: The Danish National Board of Health.
30. Sundhedsstyrelsen. (2008). Klassifikation af Sygdomme [Danish Version of International Classification of Diseases, 10th Revision]. Sygehusaesnets Klassifikationssystem (SKS). Retrieved February 25, 2010, from http://www.medinfo.dk/sks/brows.php?s_nod=4638
31. Vu, T.H., & Werb, Z. (2000). Matrix metalloproteinases: Effectors of development and normal physiology. Genes and Development, 14, 2123-2133. doi:10.1101/gad.815400
32. Yong, V.W. (2005). Metalloproteinases: Mediators of pathology and regeneration in the CNS. Nature Reviews Neuroscience, 6, 931-944. doi:10.1038/nrn1807